Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- [Data] Sales of Taisho HD’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Kyorin HD’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Shionogi’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Ono’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Santen’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Kaken’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Mochida’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Nippon Shinyaku’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Zeria’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Kissei’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Fuso's Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of ASKA's Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Nippon Chemiphar's Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Wakamoto's Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Torii’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- Regulatory Challenges Remain for Introduction of Combination Vaccines: MSD VP Shirasawa
December 12, 2012
- Fycompa Approved for Use under NHS Scotland: Eisai
December 12, 2012
- Santen to Set Up Demand-Chain Strategic Planning Office
December 12, 2012
- Astellas, UMN Complete Administration of Seasonal Vaccine to Participants in Domestic PIII Trial
December 12, 2012
- Meta-Analysis of Study Data Finds 39% Overall Response Rate with Velcade Retreatment: Takeda
December 12, 2012
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…